Obstetric Indications for Progestin Therapy.
17-OHPC
17-hydroxyprogesterone caproate
Preterm birth
Progesterone
Progestin
Journal
Obstetrics and gynecology clinics of North America
ISSN: 1558-0474
Titre abrégé: Obstet Gynecol Clin North Am
Pays: United States
ID NLM: 8709551
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Specifically, meta-analyses of randomized trials demonstrate that vaginal progesterone reduces the risk of preterm birth in selected high-risk singleton pregnancies. 17-OHPC may also reduce the risk of recurrent preterm birth in singletons. Finally, one trial suggests that vaginal progesterone may also be beneficial in improving live birth rates in singletons with prior miscarriages and early pregnancy bleeding.
Identifiants
pubmed: 36822696
pii: S0889-8545(22)00095-X
doi: 10.1016/j.ogc.2022.10.004
pii:
doi:
Substances chimiques
Progesterone
4G7DS2Q64Y
17 alpha-Hydroxyprogesterone Caproate
276F2O42F5
Progestins
0
Hydroxyprogesterones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-107Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest No conflicts of interest, financial or otherwise, to disclose.